Loading
Hit Claudin 18.2 twice: first with a plain antibody plus chemotherapy, then with an ADC or engineered cells when the cancer comes back.
Zolbetuximab + chemotherapy is approved first line; CLARITY-Gastric 01 showed an OS benefit for the CLDN18.2 ADC sonesitatug vedotin in later lines (July 2026); satri-cel CAR-T is approved in China. Whether prior zolbetuximab reduces ADC benefit (antigen persistence, ADCC-selected clones) is the key unknown.
Shares Zolbetuximab, Claudin 18.2-positive gastric cancer, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
Shares SPOTLIGHT & GLOW, Zolbetuximab, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
Shares SPOTLIGHT & GLOW, Zolbetuximab, Claudin 18.2-positive gastric cancer, Claudin 18.2.
Shares Sonesitatug vedotin, Zolbetuximab, Claudin 18.2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer.
Shares SPOTLIGHT & GLOW, Zolbetuximab, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
Shares Satricabtagene autoleucel, Claudin 18.2-positive gastric cancer, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
Shares Satricabtagene autoleucel, Claudin 18.2-positive gastric cancer, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
Shares SPOTLIGHT & GLOW, Zolbetuximab, Gastric & gastro-oesophageal junction cancer.